Antiplatelet therapy in combination with Recombinant t-PA Thrombolysis in Ischemic Stroke

Phase 3

• Conditions: ischemic stroke; 10007963; 10014523

• Registration Number: NL-OMON31665
• Lead Sponsor: Academisch Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 13 May 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 800

Inclusion Criteria

* patients with an acute ischemic stroke receiving rt-PA thrombolysis
* age * 18 years
* written informed consent is obtained

Exclusion Criteria

* known APT in the previous 5 days(in case of uncertainty the patient may be included)
* known thrombocytopenia (thrombocyte count * 100 * 10E9/l)
* known contra-indications to ASA treatment (e.g. previous adverse reaction to ASA)
* Known anticoagulans usage in the previous 5 days
* known legal incompetence of the patient prior to this stroke

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary endpoint is poor functional health at 3 months defined as<br /><br>dependency or death (mRS 3 * 6). </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcomes are symptomatic intracranial or serious systemic<br /><br>haemorrhages within 48 hours, neurological symptoms at 7 * 10 days and<br /><br>survival, disability assessed with the ALDS scale, functional health on the<br /><br>full ordinal range of the modified Rankin Scale at 3 months and the causes of<br /><br>poor outcome.</p><br>